

# GALDERMA

EST. 1981

## **Executive Summary of a Joint Working Project between Galderma (U.K.) Limited, NHS Tayside and NHS Forth Valley:**

### **“Daylight PDT @ home: Use of Photodynamic Therapy at home to treat mild to moderate Actinic Keratosis”**

This is an executive summary outlining the benefits of Galderma (U.K.) Limited (**Galderma**) working in partnership with NHS Tayside and NHS Forth Valley to assess the use of Photodynamic Therapy (**PDT**) at home as a therapeutic option for mild to moderate Actinic Keratosis (**AK**) patients (**Project**).

#### **Project summary:**

The Project is looking to deconstruct current Daylight PDT therapeutic options utilising the principles of design and realistic medicine with the aim of transforming the current Daylight PDT treatment process into a user friendly, environmentally conscious and engaging at home therapeutic option for mild to moderate AK patients. NHS Tayside (in collaboration with the University of Dundee) have designed and developed a boxed kit for use in a patient’s home which will include a prodrug and all supporting consumables for Daylight PDT treatment of mild to moderate AK in accordance with national and local guidelines which will be utilised for the purposes of the Project.

The Project aims to reduce the backlog of mild to moderate AK patients and the subsequent anticipated deterioration of AK lesions due to the reduction in diagnoses and monitoring during the COVID 19 pandemic. Key objectives include exploring more cost-effective care (cost-effective prescribing according to local guidelines, a reduction in waiting lists, reduce return visits to a hospital setting and an improvement to NHS patient experience indicators) and gaining a better understanding of the challenges faced by the NHS in delivering high-quality AK patient services and care, by realigning to a patient-centred approach with patient reported outcomes.

Galderma is committed to supporting the NHS across the dermatology field. By working in partnership and with the pooling of joint expertise and resources, Galderma, NHS Tayside and NHS Forth Valley aim to benefit AK patients by improving the delivery of effective care, facilitating the critical evaluation of that care and strengthening patient outcomes and treatment adherence.

This Project will run from April 2022 until end of March 2023.

#### **Benefits to the patients**

- Reduce the number of patients with untreated field change AK - pre-pandemic patients who were identified as mild AK may now have developed further lesions or moderate field change AK, however due to the reduction in services and government messaging to “stay at home” they may not have had appropriate follow up and management.
- Reduce the number of patients who are not achieving therapeutic targets – due to a reduction in services and the government “stay at home” messaging, many people with AK have missed their annual reviews.
- Potential reduced risk of disease progression and improvement of patient quality of life.
- Provide the patient with a timely and comfortable opportunity to be diagnosed in hospital and treated at home according to agreed protocols and increase the numbers of patients with AK who are managed in accordance with British Association of Dermatologists guidance.
- Reduce unplanned admissions due to poor management and compliance.
- In the long-term, this approach aims to prevent disease progression, reducing hospital admissions and therefore, reduce cross infection and improve quality of life for patients.

#### **Benefit to the NHS**

- Helping to reduce the backlog of poorly managed or un-treated AK patients which has worsened due to the COVID 19 pandemic.
- In the long-term, preventing disease progression and improving adherence to care plans through self-management and as a result, potentially reduce hospital admissions.
- A huge challenge is being faced in treating dermatology patients in alignment with the specific needs of the local healthcare economy. The Daylight PDT @home kit will be tailored to support this, and in turn support the Health Board and patients by providing the opportunity to effectively manage in a more timely and cost-effective manner to reduce patient visits to specialist care and prevent disease progression.

#### **Benefit to Galderma**

- Demonstrate Galderma UK as a trusted partner through deployment of skills & resources to support higher quality care for Dermatology patients.
- An improved relationship with NHS Tayside and NHS Forth Valley and overall, with NHS Scotland.
- The Project may benefit Galderma indirectly from changes in clinical behaviour through National Dermatology guidelines.
- Potential for extension to other parts of the UK benefiting NHS and patients.
- Increased throughput of AK patients may lead to increased prescription of licensed treatments, which may include Galderma’s licensed prodrug.

Job code: UKI-MVR-2200013

Date of preparation: March 2022